Last reviewed · How we verify
NCT06657521: OIMP
Osteoimplant and Dental Implants Stability
EARLY_PHASE1 trial testing osteoimplant in Primary Stability of the Implants in 60 participants. Not yet recruiting.
31 December 2025
Quick facts
| Lead sponsor | Universidad de Granada |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 1 January 2025 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2025 |
Drugs / interventions tested
- osteoimplant — full drug profile →
- Placebo Oral Tablet — full drug profile →
Conditions studied
- Primary Stability of the Implants — all drugs for Primary Stability of the Implants →
- Pain — all drugs for Pain →
Sponsor
Universidad de Granada — full company profile →
Who can join
18 and older, any sex, with Primary Stability of the Implants or Pain. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Based on the scientific evidence, the relevance of this subject, we consider this study to be justified, the general or specific objective of which is as follows: 'To evaluate the effect of the administration of Osteoimplant© and Osteoimplant Complex© as a food supplement in obtaining implant stability and in the healing of dental implant surgery'. As secondary objectives, we will also evaluate the effect of Osteoimplant© and Osteoimplant Complex© on pain, postoperative inflammation and soft tissue healing. The sample will consist of 60 patients. The sample will be randomly divided into 2 groups using a randomisation table generated by a statistical programme. For blinding, neither the patient nor the operator shall be aware of the group to which each patient belongs. To ensure blinding, medication will be delivered in sealed, opaque envelopes. Patients shall be assigned to one of the following groups: * Group I: 30 patients prescribed to take Osteoimplant Complex© on the following schedule: 2 tablets per day starting 5 days before implant placement and 1 tablet per day of Osteimplant© for 2 months after implant placement. * Group II: 30 patients who were prescribed placebo with the following regimen: 2 tablets per day starting 5 days before implant placement and 1 tablet per day for 2 months after implant placement.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06657521
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of osteoimplant
Trials testing the same drug.
- NCT06664060 — Osteoimplant and Bone Healing · EARLY_PHASE1 · not yet recruiting
Other Universidad de Granada trials
Trials by the same sponsor.
- NCT07497698 — Saffron Extract Supplementation and Sleep Quality in Middle-Aged Adults · NA · recruiting
- NCT07528924 — TuJugling: Comparing Two Juggling Learning Methods in College Students · NA · recruiting
- NCT07388134 — Virtual Reality Based High-intensity Interval Training in Chronic Low Back Pain · NA · active not recruiting
- NCT07494916 — Effects of Functional Task Training on Muscle Health and Function in Older Adults With Sarcopenia · NA · active not recruiting
- NCT06518200 — Preventing Breast Cancer Therapy-related Cardiovascular Toxicity With a Daily-adapted Program With Mhealth Support · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06657521 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Universidad de Granada
- Last refreshed: 24 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06657521.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing